The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fast Track, 2002Further evaluation fo the neuroprotective effects of citrus flavenoid tangeretin in a pre-clinical model of PD
Previously, Dr. Dexter's team has demonstrated that neurodegeneration in Parkinson's disease (PD) is associated with a process called oxidative stress. Oxidative stress is caused by either an increase...
-
Fast Track, 2002Dyskinesia & Abnormal Regulation of DARPP-32
L-DOPA-induced dyskinesia (abnormal involuntary movements, AIMs) is a major complication of the pharmacotherapy of Parkinson's disease. Subjects suffering from L-DOPA-induced dyskinesia show complex...
-
Fast Track, 2002Prevention and Treatment of Parkinson’s Disease Pathology in a-Synuclein Transgenic Mice
The hallmark lesions in the brains of patients with Parkinson's disease (termed Lewy bodies) are mainly composed of a-synuclein. This small protein normally regulates proper communication between...
-
Fast Track, 2002Dynamical interactions between basal ganglia structures and cerebral Cortex: an in Vivo Multi-site Recording Study
Recent successful strategies in treating Parkinson's disease consist of placing selective lesions in globus pallidus or stimulating in subthalamic nucleus (deep brain stimulation). Yet the dynamical...
-
Community Fast Track, 2002VDA Agonist Neuroprotection via AKT Pathway in MPTP Pre-clinical Model of Parkinson's
Antiparkinsonian agents that are direct dopamine (DA) agonists, such pramipexole, have shown to be neuroprotective against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced damage to the DA...
-
Fast Track, 2002Study of the Metabolism and Aggregation of Alpha-synuclein in Parkin-depleted Neuronal Cells
While only a small fraction of Parkinson's disease (PD) cases are genetic, they possess most of the common clinical and pathological features of PD, which ordinarily has no traceable cause. As this...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.